---
title: "Johnson & Johnson (JNJ) Revenue"
description: "Johnson and Johnson annual revenue and earnings history from 2014 to 2025. Pharmaceutical segment, MedTech, Kenvue spin-off impact, and dividend growth history."
canonical: https://www.getswoopr.com/tables/company/johnson-and-johnson-revenue-earnings-history/
source: "Swoopr Investment: https://www.getswoopr.com"
---

## Direct Answer



> Johnson & Johnson reported $88.8 billion in revenue for 2024 and $94.2 billion for 2025, after separating its consumer health segment (Kenvue) in 2023. The remaining J&J focuses on MedTech (surgical instruments, orthopaedics) and Innovative Medicine (pharmaceuticals). J&J is a Dividend King, having increased its dividend for 63 consecutive years.








# Johnson & Johnson (JNJ) Annual Revenue and Earnings History



## Johnson & Johnson annual revenue, net income, adjusted EPS, and dividend per share (2014-2025)



| Year | Revenue (B) | Net Income (B) | Adj. EPS | Dividend/Share |
| --- | --- | --- | --- | --- |
| 2014 | $74.3 | $16.3 | $5.70 | $2.76 |
| 2016 | $71.9 | $16.5 | $6.73 | $3.15 |
| 2018 | $81.6 | $15.3 | $8.18 | $3.54 |
| 2019 | $82.1 | $15.1 | $8.68 | $3.75 |
| 2020 | $82.6 | $14.7 | $8.03 | $4.04 |
| 2021 | $93.8 | $20.9 | $9.80 | $4.24 |
| 2022 | $94.9 | $17.9 | $10.15 | $4.52 |
| 2023 | $85.2 | $35.2 | $9.92 | $4.70 |
| 2024 | $88.8 | $14.1 | $9.98 | $4.91 |
| 2025 | $94.2 | $26.8 | $10.79 | $5.14 |

![Line chart of Johnson & Johnson annual revenue, net income, adjusted EPS, and dividend per share (2014-2025), 2014 to 2025, with 2 series. Revenue (B) starts at $74.3, peaks at $94.9 in 2022, falls to a low of $71.9 in 2016 and ends at $94.2 in 2025.](https://www.getswoopr.com/images/charts/tables-company-johnson-and-johnson-revenue-earnings-history-1.webp)
*Johnson & Johnson annual revenue, net income, adjusted EPS, and dividend per share (2014-2025), charted from the table above. Select the chart to open it full size.*



Source: [Johnson & Johnson Investor Relations](https://www.investor.jnj.com/). Note: 2023 net income includes Kenvue spin-off gain; consumer segment brands (Tylenol, Band-Aid, Neutrogena) separated into Kenvue (KVUE) in May 2023. Last verified: October 2026. Adjusted EPS from 2023 is on the continuing-operations basis J&J reports after the Kenvue separation; earlier years are as first reported.



## Frequently asked questions



Why did J&J spin off its consumer segment?

J&J separated its consumer health brands (Tylenol, Band-Aid, Listerine, Neutrogena) into a new company called Kenvue (ticker: KVUE) in May 2023. The rationale: consumer health is a lower-growth, lower-margin business (approximately 4-6% margins) compared to pharmaceuticals (35-40% operating margins) and MedTech. Separating them allows each company to focus capital, executive attention, and valuation multiples more appropriately: Kenvue valued as a consumer staples company, J&J valued as a pharma/MedTech company. J&J retained approximately 9% of Kenvue initially, distributing the rest to J&J shareholders. This is a common pure-play separation strategy.



What are J&J's key pharmaceutical products?

J&J's Innovative Medicine segment (formerly Janssen) markets several blockbuster drugs: Stelara (ustekinumab) for Crohn's disease and psoriasis ($9.7B revenue in 2022); Darzalex (daratumumab) for multiple myeloma ($8.0B in 2022, growing 25%+); Tremfya for psoriasis; Erleada for prostate cancer; and various immunology drugs. Stelara faces biosimilar competition beginning 2025 (patent expiration), which will significantly reduce its revenue. J&J's pipeline includes CAR-T cancer therapies and bispecific antibodies as next-generation growth drivers. The pharmaceutical segment generates approximately 55-60% of J&J's total revenue post-spin.



What does Dividend King status mean for J&J?

A Dividend King is a company that has increased its annual dividend for 50+ consecutive years. Johnson & Johnson has raised its dividend for 62+ consecutive years as of 2024, making it one of approximately 50 companies in this elite category. The dividend has compounded at approximately 6% annually over the past decade, from $2.76/share in 2014 to approximately $4.96/share estimated in 2024. J&J's payout ratio is approximately 46% of adjusted EPS, conservative enough to maintain dividend safety even in difficult pharmaceutical market conditions. Dividend Kings are prized by income investors for reliability, though yield is typically modest (approximately 3% as of 2024).







## Cite This Page



If you reference this table in your own work, use the following citation format and add the date you accessed it:



> Swoopr Editorial Team. (2026). *Johnson & Johnson (JNJ) Annual Revenue and Earnings History*. Swoopr Investment. [https://www.getswoopr.com/tables/company/johnson-and-johnson-revenue-earnings-history/](https://www.getswoopr.com/tables/company/johnson-and-johnson-revenue-earnings-history/)



Check the figures against the primary sources listed under References before you rely on or republish them; the series they come from are revised.







## References



- [Johnson & Johnson: Investor Relations](https://www.investor.jnj.com/)







[Swoopr Editorial Team](https://www.getswoopr.com/authors/swoopr-editorial-team/) produces independent investment education and research content.



Corrections: [corrections policy](https://www.getswoopr.com/legal/corrections-policy/). Standards: [editorial standards](https://www.getswoopr.com/legal/editorial-policy/).